Published in Infect Immun on January 22, 2008
New insights into acquisition, boosting, and longevity of immunity to malaria in pregnant women. J Infect Dis (2012) 2.52
Using serological measures to monitor changes in malaria transmission in Vanuatu. Malar J (2010) 2.47
Long-lived antibody and B Cell memory responses to the human malaria parasites, Plasmodium falciparum and Plasmodium vivax. PLoS Pathog (2010) 2.30
Extreme polymorphism in a vaccine antigen and risk of clinical malaria: implications for vaccine development. Sci Transl Med (2009) 1.95
Analysis of immunity to febrile malaria in children that distinguishes immunity from lack of exposure. Infect Immun (2009) 1.79
Associations between Burkitt lymphoma among children in Malawi and infection with HIV, EBV and malaria: results from a case-control study. PLoS One (2008) 1.70
B cell sub-types following acute malaria and associations with clinical immunity. Malar J (2016) 1.39
Force of infection is key to understanding the epidemiology of Plasmodium falciparum malaria in Papua New Guinean children. Proc Natl Acad Sci U S A (2012) 1.33
Atypical and classical memory B cells produce Plasmodium falciparum neutralizing antibodies. J Exp Med (2013) 1.31
Continuing intense malaria transmission in northern Uganda. Am J Trop Med Hyg (2011) 1.30
Memory B cells are a more reliable archive for historical antimalarial responses than plasma antibodies in no-longer exposed children. Proc Natl Acad Sci U S A (2012) 1.18
Submicroscopic and asymptomatic Plasmodium falciparum and Plasmodium vivax infections are common in western Thailand - molecular and serological evidence. Malar J (2015) 1.17
Functional memory B cells and long-lived plasma cells are generated after a single Plasmodium chabaudi infection in mice. PLoS Pathog (2009) 1.15
The breadth, but not the magnitude, of circulating memory B cell responses to P. falciparum increases with age/exposure in an area of low transmission. PLoS One (2011) 1.14
Serological markers for monitoring historical changes in malaria transmission intensity in a highly endemic region of Western Kenya, 1994-2009. Malar J (2014) 1.14
Novel serologic biomarkers provide accurate estimates of recent Plasmodium falciparum exposure for individuals and communities. Proc Natl Acad Sci U S A (2015) 1.13
New antigens for a multicomponent blood-stage malaria vaccine. Sci Transl Med (2014) 1.11
Estimation of recent and long-term malaria transmission in a population by antibody testing to multiple Plasmodium falciparum antigens. J Infect Dis (2014) 1.07
The dynamics of naturally acquired immune responses to Plasmodium falciparum sexual stage antigens Pfs230 & Pfs48/45 in a low endemic area in Tanzania. PLoS One (2010) 1.06
Immune escape by Epstein-Barr virus associated malignancies. Semin Cancer Biol (2008) 1.02
Young lives lost as B cells falter: what we are learning about antibody responses in malaria. J Immunol (2013) 1.02
High levels of IgG3 anti ICB2-5 in Plasmodium vivax-infected individuals who did not develop symptoms. Malar J (2013) 1.02
Boosting antibody responses to Plasmodium falciparum merozoite antigens in children with highly seasonal exposure to infection. Parasite Immunol (2010) 1.01
Opsonising antibodies to P. falciparum merozoites associated with immunity to clinical malaria. PLoS One (2013) 1.01
Plasmodium falciparum malaria in the Peruvian Amazon, a region of low transmission, is associated with immunologic memory. Infect Immun (2012) 0.99
Acquisition of antibody isotypes against Plasmodium falciparum blood stage antigens in a birth cohort. Parasite Immunol (2010) 0.97
Increased sensitivity for detecting malaria parasites in human umbilical cord blood using scaled-up DNA preparation. Malar J (2012) 0.96
The relationship of Plasmodium falciparum humeral immunity with HIV-1 immunosuppression and treatment efficacy in Zambia. Malar J (2009) 0.96
Infection and treatment immunizations for successful parasite vaccines. Trends Parasitol (2013) 0.94
Allele-specific antibodies to Plasmodium falciparum merozoite surface protein-2 and protection against clinical malaria. Parasite Immunol (2010) 0.94
Heritability of antibody isotype and subclass responses to Plasmodium falciparum antigens. PLoS One (2009) 0.94
Malaria-associated atypical memory B cells exhibit markedly reduced B cell receptor signaling and effector function. Elife (2015) 0.94
Research priorities for the development and implementation of serological tools for malaria surveillance. F1000Prime Rep (2014) 0.94
Clearance of asymptomatic P. falciparum Infections Interacts with the number of clones to predict the risk of subsequent malaria in Kenyan children. PLoS One (2011) 0.93
Immunological consequences of intermittent preventive treatment against malaria in Senegalese preschool children. Malar J (2010) 0.93
Long-lived Plasmodium falciparum specific memory B cells in naturally exposed Swedish travelers. Eur J Immunol (2013) 0.92
A mathematical model of seropositivity to malaria antigen, allowing seropositivity to be prolonged by exposure. Malar J (2014) 0.91
Acute Disruption of Bone Marrow B Lymphopoiesis and Apoptosis of Transitional and Marginal Zone B Cells in the Spleen following a Blood-Stage Plasmodium chabaudi Infection in Mice. J Parasitol Res (2011) 0.90
Common asymptomatic and submicroscopic malaria infections in Western Thailand revealed in longitudinal molecular and serological studies: a challenge to malaria elimination. Malar J (2016) 0.89
Antibody acquisition models: A new tool for serological surveillance of malaria transmission intensity. Sci Rep (2016) 0.87
Toward a surrogate marker of malaria exposure: modeling longitudinal antibody measurements under outbreak conditions. PLoS One (2011) 0.85
Seasonality in malaria transmission: implications for case-management with long-acting artemisinin combination therapy in sub-Saharan Africa. Malar J (2015) 0.84
High antibody responses against Plasmodium falciparum in immigrants after extended periods of interrupted exposure to malaria. PLoS One (2013) 0.84
The design and statistical power of treatment re-infection studies of the association between pre-erythrocytic immunity and infection with Plasmodium falciparum. Malar J (2013) 0.84
Biosignatures of Exposure/Transmission and Immunity. Am J Trop Med Hyg (2015) 0.84
Sample size and power calculations for detecting changes in malaria transmission using antibody seroconversion rate. Malar J (2015) 0.83
Immunoprofiling of the tryptophan-rich antigen family in Plasmodium vivax. Infect Immun (2015) 0.83
Developmental allometry and paediatric malaria. Malar J (2012) 0.82
B-cell responses to pregnancy-restricted and -unrestricted Plasmodium falciparum erythrocyte membrane protein 1 antigens in Ghanaian women naturally exposed to malaria parasites. Infect Immun (2014) 0.82
Relationship between malaria incidence and IgG levels to Plasmodium falciparum merozoite antigens in Malian children: impact of hemoglobins S and C. PLoS One (2013) 0.82
Humoral immune response to Plasmodium falciparum vaccine candidate GMZ2 and its components in populations naturally exposed to seasonal malaria in Ethiopia. Malar J (2013) 0.82
Predicting antidisease immunity using proteome arrays and sera from children naturally exposed to malaria. Mol Cell Proteomics (2014) 0.81
Estimating malaria transmission intensity from Plasmodium falciparum serological data using antibody density models. Malar J (2016) 0.80
Malaria and immunity during pregnancy and postpartum: a tale of two species. Parasitology (2015) 0.80
Multiple clinical episodes of Plasmodium falciparum malaria in a low transmission intensity setting: exposure versus immunity. BMC Med (2015) 0.79
Temporal and spatial patterns of serologic responses to Plasmodium falciparum antigens in a region of declining malaria transmission in southern Zambia. Malar J (2012) 0.79
The Malaria-High Blood Pressure Hypothesis. Circ Res (2016) 0.79
Differing rates of antibody acquisition to merozoite antigens in malaria: implications for immunity and surveillance. J Leukoc Biol (2016) 0.78
Differential immune response associated to malaria outcome is detectable in peripheral blood following Plasmodium yoelii infection in mice. PLoS One (2014) 0.78
Differences in affinity of monoclonal and naturally acquired polyclonal antibodies against Plasmodium falciparum merozoite antigens. BMC Microbiol (2015) 0.77
Novel flow cytometry technique for detection of Plasmodium falciparum specific B-cells in humans: increased levels of specific B-cells in ongoing infection. Malar J (2015) 0.76
The effect of declining exposure on T cell-mediated immunity to Plasmodium falciparum - an epidemiological "natural experiment". BMC Med (2016) 0.76
Serological signatures of declining exposure following intensification of integrated malaria control in two rural Senegalese communities. PLoS One (2017) 0.76
Post-exposure serological responses to malaria parasites in potential blood donors. Malar J (2016) 0.75
Merozoite Antigens of Plasmodium falciparum Elicit Strain-Transcending Opsonizing Immunity. Infect Immun (2016) 0.75
Parasite Specific Antibody Increase Induced by an Episode of Acute P. falciparum Uncomplicated Malaria. PLoS One (2015) 0.75
Measuring changes in transmission of neglected tropical diseases, malaria, and enteric pathogens from quantitative antibody levels. PLoS Negl Trop Dis (2017) 0.75
Development of Plasmodium falciparum specific naïve, atypical, memory and plasma B cells during infancy and in adults in an endemic area. Malar J (2017) 0.75
A longitudinal cohort study of malaria exposure and changing serostatus in a malaria endemic area of rural Tanzania. Malar J (2017) 0.75
Waning Immunity and Microbial Vaccines-Workshop of the National Institute of Allergy and Infectious Diseases. Clin Vaccine Immunol (2017) 0.75
T follicular helper cells regulate the activation of B lymphocytes and antibody production during Plasmodium vivax infection. PLoS Pathog (2017) 0.75
Acquisition, maintenance and adaptation of invasion inhibitory antibodies against Plasmodium falciparum invasion ligands involved in immune evasion. PLoS One (2017) 0.75
A Unique Subset of γδ T Cells Expands and Produces IL-10 in Patients with Naturally Acquired Immunity against Falciparum Malaria. Front Microbiol (2017) 0.75
A malaria vaccine protects Aotus monkeys against virulent Plasmodium falciparum infection. NPJ Vaccines (2017) 0.75
Mortality and morbidity from malaria among children in a rural area of The Gambia, West Africa. Trans R Soc Trop Med Hyg (1987) 6.58
Estimating medium- and long-term trends in malaria transmission by using serological markers of malaria exposure. Proc Natl Acad Sci U S A (2005) 6.39
Humoral immunity due to long-lived plasma cells. Immunity (1998) 6.35
Antibodies to blood stage antigens of Plasmodium falciparum in rural Gambians and their relation to protection against infection. Trans R Soc Trop Med Hyg (1990) 4.70
Human antibodies to recombinant protein constructs of Plasmodium falciparum Apical Membrane Antigen 1 (AMA1) and their associations with protection from malaria. Vaccine (2004) 3.51
Metabolic properties of IgG subclasses in man. J Clin Invest (1970) 3.48
Maintenance of serum antibody levels. Annu Rev Immunol (2005) 3.20
A longitudinal study of type-specific antibody responses to Plasmodium falciparum merozoite surface protein-1 in an area of unstable malaria in Sudan. J Immunol (1998) 2.94
Expression of the 19-kilodalton carboxy-terminal fragment of the Plasmodium falciparum merozoite surface protein-1 in Escherichia coli as a correctly folded protein. Mol Biochem Parasitol (1994) 2.71
Does malaria suffer from lack of memory? Immunol Rev (2004) 2.66
IgG3 antibodies to Plasmodium falciparum merozoite surface protein 2 (MSP2): increasing prevalence with age and association with clinical immunity to malaria. Am J Trop Med Hyg (1998) 2.41
Purification, characterization, and immunogenicity of the refolded ectodomain of the Plasmodium falciparum apical membrane antigen 1 expressed in Escherichia coli. Infect Immun (2002) 2.37
A longitudinal investigation of IgG and IgM antibody responses to the merozoite surface protein-1 19-kiloDalton domain of Plasmodium falciparum in pregnant women and infants: associations with febrile illness, parasitemia, and anemia. Am J Trop Med Hyg (1998) 2.33
IgG antibody responses to Plasmodium falciparum merozoite antigens in Kenyan children have a short half-life. Malar J (2007) 2.30
Profiling the antibody immune response against blood stage malaria vaccine candidates. Clin Chem (2007) 2.23
Malaria-induced acquisition of antibodies to Plasmodium falciparum variant surface antigens. Infect Immun (2002) 2.00
High levels of serum antibodies to merozoite surface protein 2 of Plasmodium falciparum are associated with reduced risk of clinical malaria in coastal Kenya. Vaccine (2005) 1.89
Target antigen, age, and duration of antigen exposure independently regulate immunoglobulin G subclass switching in malaria. Infect Immun (2006) 1.87
Selective recognition of malaria antigens by human serum antibodies is not genetically determined but demonstrates some features of clonal imprinting. Int Immunol (1996) 1.75
Analysis of human antibodies to erythrocyte binding antigen 175 of Plasmodium falciparum. Infect Immun (2000) 1.66
Kinetics of antibody responses to Plasmodium falciparum-infected erythrocyte variant surface antigens. J Infect Dis (2003) 1.57
Serum antibodies to capsular polysaccharide vaccine of group A Neissera meningitidis followed for three years in infants and children. J Infect Dis (1980) 1.53
Genetic diversity and antigenic polymorphism in Plasmodium falciparum: extensive serological cross-reactivity between allelic variants of merozoite surface protein 2. Infect Immun (2003) 1.44
Differential patterns of human immunoglobulin G subclass responses to distinct regions of a single protein, the merozoite surface protein 1 of Plasmodium falciparum. Infect Immun (2001) 1.44
Studies on the persistence of malarial antibody response. Am J Epidemiol (1968) 1.35
Sero-epidemiological studies on population groups previously exposed to malaria. Lancet (1972) 1.23
Malaria vaccines: the stage we are at. Nat Rev Microbiol (2007) 1.18
Immunoglobulin G (IgG) responses to Plasmodium falciparum glycosylphosphatidylinositols are short-lived and predominantly of the IgG3 subclass. J Infect Dis (2003) 1.16
Analysis of T helper and antigen-presenting cell functions in cord blood and peripheral blood leukocytes from healthy children of different ages. J Clin Invest (1993) 1.15
Reduced ability of neonatal and early-life bone marrow stromal cells to support plasmablast survival. J Immunol (2006) 1.12
High road, low road? Choices and challenges on the pathway to a malaria vaccine. Parasitology (2006) 1.10
Baculovirus-mediated expression of Plasmodium falciparum erythrocyte binding antigen 175 polypeptides and their recognition by human antibodies. Infect Immun (1997) 1.07
Delayed and deficient establishment of the long-term bone marrow plasma cell pool during early life. Eur J Immunol (2001) 0.99
Age, sex, and household exposure are associated with the acute measles-specific antibody-dependent cellular cytotoxicity antibody response. J Infect Dis (1995) 0.85
A large focus of naturally acquired Plasmodium knowlesi infections in human beings. Lancet (2004) 12.21
Plasmodium knowlesi malaria in humans is widely distributed and potentially life threatening. Clin Infect Dis (2008) 9.87
Changes in malaria indices between 1999 and 2007 in The Gambia: a retrospective analysis. Lancet (2008) 9.05
Multiple populations of artemisinin-resistant Plasmodium falciparum in Cambodia. Nat Genet (2013) 5.22
Analysis of Plasmodium falciparum diversity in natural infections by deep sequencing. Nature (2012) 4.37
Genome-wide and fine-resolution association analysis of malaria in West Africa. Nat Genet (2009) 4.30
Reduction of malaria transmission to Anopheles mosquitoes with a six-dose regimen of co-artemether. PLoS Med (2005) 3.91
Breadth and magnitude of antibody responses to multiple Plasmodium falciparum merozoite antigens are associated with protection from clinical malaria. Infect Immun (2008) 3.51
Human antibodies to recombinant protein constructs of Plasmodium falciparum Apical Membrane Antigen 1 (AMA1) and their associations with protection from malaria. Vaccine (2004) 3.51
Effect of two different house screening interventions on exposure to malaria vectors and on anaemia in children in The Gambia: a randomised controlled trial. Lancet (2009) 3.45
Multiple origins and regional dispersal of resistant dhps in African Plasmodium falciparum malaria. PLoS Med (2009) 3.38
A field trial to assess a blood-stage malaria vaccine. N Engl J Med (2011) 3.20
A CD4(+) T-cell immune response to a conserved epitope in the circumsporozoite protein correlates with protection from natural Plasmodium falciparum infection and disease. Nat Med (2004) 2.93
Plasmodium falciparum merozoite surface protein 3 is a target of allele-specific immunity and alleles are maintained by natural selection. J Infect Dis (2006) 2.75
Quantitative detection of Plasmodium falciparum DNA in saliva, blood, and urine. J Infect Dis (2009) 2.64
Standardized data collection for multi-center clinical studies of severe malaria in African children: establishing the SMAC network. Trans R Soc Trop Med Hyg (2006) 2.52
Risk factors for house-entry by malaria vectors in a rural town and satellite villages in The Gambia. Malar J (2008) 2.51
Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A. PLoS One (2009) 2.49
Continued decline of malaria in The Gambia with implications for elimination. PLoS One (2010) 2.47
Plasmodium knowlesi: reservoir hosts and tracking the emergence in humans and macaques. PLoS Pathog (2011) 2.45
Purification, characterization, and immunogenicity of the refolded ectodomain of the Plasmodium falciparum apical membrane antigen 1 expressed in Escherichia coli. Infect Immun (2002) 2.37
IgG antibody responses to Plasmodium falciparum merozoite antigens in Kenyan children have a short half-life. Malar J (2007) 2.30
Gambian children successfully treated with chloroquine can harbor and transmit Plasmodium falciparum gametocytes carrying resistance genes. Am J Trop Med Hyg (2002) 2.25
Culturally compelling strategies for behaviour change: a social ecology model and case study in malaria prevention. Soc Sci Med (2005) 2.25
Isolation of viable Plasmodium falciparum merozoites to define erythrocyte invasion events and advance vaccine and drug development. Proc Natl Acad Sci U S A (2010) 2.25
Profiling the antibody immune response against blood stage malaria vaccine candidates. Clin Chem (2007) 2.23
Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research. Vaccine (2005) 2.18
Structural basis of antigenic escape of a malaria vaccine candidate. Proc Natl Acad Sci U S A (2007) 2.15
Invasion-inhibitory antibodies inhibit proteolytic processing of apical membrane antigen 1 of Plasmodium falciparum merozoites. Proc Natl Acad Sci U S A (2003) 2.01
Antibodies to Plasmodium falciparum antigens predict a higher risk of malaria but protection from symptoms once parasitemic. J Infect Dis (2011) 1.98
Allelic heterogeneity of G6PD deficiency in West Africa and severe malaria susceptibility. Eur J Hum Genet (2009) 1.94
Addition of artesunate to chloroquine for treatment of Plasmodium falciparum malaria in Gambian children causes a significant but short-lived reduction in infectiousness for mosquitoes. Trop Med Int Health (2004) 1.93
Safety and immunogenicity of an AMA-1 malaria vaccine in Malian adults: results of a phase 1 randomized controlled trial. PLoS One (2008) 1.90
High levels of serum antibodies to merozoite surface protein 2 of Plasmodium falciparum are associated with reduced risk of clinical malaria in coastal Kenya. Vaccine (2005) 1.89
Erythrocyte invasion phenotypes of Plasmodium falciparum in The Gambia. Infect Immun (2003) 1.85
Allele frequency-based analyses robustly map sequence sites under balancing selection in a malaria vaccine candidate antigen. Genetics (2003) 1.82
Distinct roles for FOXP3 and FOXP3 CD4 T cells in regulating cellular immunity to uncomplicated and severe Plasmodium falciparum malaria. PLoS Pathog (2009) 1.81
Serum IgG3 to the Plasmodium falciparum merozoite surface protein 2 is strongly associated with a reduced prospective risk of malaria. Parasite Immunol (2003) 1.77
Anopheles gambiae complex along The Gambia river, with particular reference to the molecular forms of An. gambiae s.s. Malar J (2008) 1.76
High spatial resolution mapping of malaria transmission risk in the Gambia, west Africa, using LANDSAT TM satellite imagery. Am J Trop Med Hyg (2007) 1.74
A decline in the incidence of invasive non-typhoidal Salmonella infection in The Gambia temporally associated with a decline in malaria infection. PLoS One (2010) 1.72
Common variation in the ABO glycosyltransferase is associated with susceptibility to severe Plasmodium falciparum malaria. Hum Mol Genet (2007) 1.72
Combination therapy counteracts the enhanced transmission of drug-resistant malaria parasites to mosquitoes. Antimicrob Agents Chemother (2004) 1.71
A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults. PLoS Med (2004) 1.70
Correlation of high levels of antibodies to multiple pre-erythrocytic Plasmodium falciparum antigens and protection from infection. Am J Trop Med Hyg (2005) 1.70
The effect of mass administration of sulfadoxine-pyrimethamine combined with artesunate on malaria incidence: a double-blind, community-randomized, placebo-controlled trial in The Gambia. Trans R Soc Trop Med Hyg (2003) 1.69
Chloroquine/sulphadoxine-pyrimethamine for gambian children with malaria: transmission to mosquitoes of multidrug-resistant Plasmodium falciparum. PLoS Clin Trials (2006) 1.69
Genetic structure of Plasmodium falciparum populations in the Brazilian Amazon region. J Infect Dis (2004) 1.68
Evidence for diversifying selection on erythrocyte-binding antigens of Plasmodium falciparum and P. vivax. Genetics (2003) 1.67
RTS,S/AS02A malaria vaccine does not induce parasite CSP T cell epitope selection and reduces multiplicity of infection. PLoS Clin Trials (2006) 1.65
Comparison of surveillance methods applied to a situation of low malaria prevalence at rural sites in The Gambia and Guinea Bissau. Malar J (2009) 1.63
Gametocytaemia after drug treatment of asymptomatic Plasmodium falciparum. PLoS Clin Trials (2006) 1.63
Two strategies for the delivery of IPTc in an area of seasonal malaria transmission in the Gambia: a randomised controlled trial. PLoS Med (2011) 1.61
Antibodies to the N-terminal block 2 of Plasmodium falciparum merozoite surface protein 1 are associated with protection against clinical malaria. Infect Immun (2004) 1.60
Phase 1 evaluation of 3 highly immunogenic prime-boost regimens, including a 12-month reboosting vaccination, for malaria vaccination in Gambian men. J Infect Dis (2004) 1.58
Haplotypic analysis of the TNF locus by association efficiency and entropy. Genome Biol (2003) 1.55
Population genomic scan for candidate signatures of balancing selection to guide antigen characterization in malaria parasites. PLoS Genet (2012) 1.55
Positive selection of a CD36 nonsense variant in sub-Saharan Africa, but no association with severe malaria phenotypes. Hum Mol Genet (2009) 1.50
A nonadjuvanted polypeptide nanoparticle vaccine confers long-lasting protection against rodent malaria. J Immunol (2009) 1.50
High antibody titer against apical membrane antigen-1 is required to protect against malaria in the Aotus model. PLoS One (2009) 1.48
Carriage of chloroquine-resistant parasites and delay of effective treatment increase the risk of severe malaria in Gambian children. J Infect Dis (2005) 1.47
Protective efficacy of the RTS,S/AS02 Plasmodium falciparum malaria vaccine is not strain specific. Am J Trop Med Hyg (2003) 1.45
Update on the clinical development of candidate malaria vaccines. Am J Trop Med Hyg (2004) 1.45
Population genetic structure of Plasmodium falciparum across a region of diverse endemicity in West Africa. Malar J (2012) 1.44
Fragmented population structure of plasmodium falciparum in a region of declining endemicity. J Infect Dis (2005) 1.42
The addition of artesunate to chloroquine for treatment of Plasmodium falciparum malaria in Gambian children delays, but does not prevent treatment failure. Am J Trop Med Hyg (2003) 1.41
Differential evidence of natural selection on two leading sporozoite stage malaria vaccine candidate antigens. Int J Parasitol (2006) 1.40
Randomised trial of chloroquine/sulphadoxine-pyrimethamine in Gambian children with malaria: impact against multidrug-resistant P. falciparum. PLoS Clin Trials (2006) 1.39
Allele frequency-based and polymorphism-versus-divergence indices of balancing selection in a new filtered set of polymorphic genes in Plasmodium falciparum. Mol Biol Evol (2010) 1.38
Repeat sequences in block 2 of Plasmodium falciparum merozoite surface protein 1 are targets of antibodies associated with protection from malaria. Infect Immun (2003) 1.37
Natural selection on the erythrocyte surface. Mol Biol Evol (2002) 1.37
Malaria infection, morbidity and transmission in two ecological zones Southern Ghana. Afr J Health Sci (1995) 1.36
Induction of strain-transcending antibodies against Group A PfEMP1 surface antigens from virulent malaria parasites. PLoS Pathog (2012) 1.35
Safety and immunogenicty of RTS,S/AS02A candidate malaria vaccine in Gambian children. Vaccine (2005) 1.35
Protective antibody and CD8+ T-cell responses to the Plasmodium falciparum circumsporozoite protein induced by a nanoparticle vaccine. PLoS One (2012) 1.35
Statistical estimation of cell-cycle progression and lineage commitment in Plasmodium falciparum reveals a homogeneous pattern of transcription in ex vivo culture. Proc Natl Acad Sci U S A (2009) 1.35
Risk factors for and clinical outcome of congenital cytomegalovirus infection in a peri-urban West-African birth cohort. PLoS One (2007) 1.33
Airflow attenuation and bed net utilization: observations from Africa and Asia. Malar J (2012) 1.32
Mode of action of invasion-inhibitory antibodies directed against apical membrane antigen 1 of Plasmodium falciparum. Infect Immun (2005) 1.32
Antibodies to pre-erythrocytic Plasmodium falciparum antigens and risk of clinical malaria in Kenyan children. J Infect Dis (2008) 1.32
Detecting signatures of balancing selection to identify targets of anti-parasite immunity. Trends Parasitol (2010) 1.31
Is mosquito larval source management appropriate for reducing malaria in areas of extensive flooding in The Gambia? A cross-over intervention trial. Am J Trop Med Hyg (2010) 1.29